Craft

MeiraGTx

Stock Price

$5.8

2024-10-29

Market Capitalization

$453.8 M

2024-10-29

Revenue

$81.4 M

FY, 2025

MeiraGTx Summary

Company Summary

Overview
MeiraGTx is a gene therapy company, which is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The Company is pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. MeiraGTx is also developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration.
Type
Public
Status
Active
Founded
2015
HQ
New York, NY, US | view all locations
Website
http://meiragtx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Keith R. Harris, Chairman of the Board

    • Alexandria Forbes

      Alexandria Forbes, President, Chief Executive Officer

    • Richard Giroux

      Richard Giroux, Chief Operating Officer and Chief Financial Officer

    • Ellen Hukkelhoven, Board Member

      LocationsView all

      4 locations detected

      • New York, NY HQ

        United States

        450 E 29th St 15th Floor

      • Amsterdam, NH

        Netherlands

        Paalbergweg 2-4

      • London, England

        United Kingdom

        92 Britannia Walk, Hoxton

      • London, England

        United Kingdom

        Fortress Studios Ltd, 34-38 Provost St

      MeiraGTx Financials

      Summary Financials

      Revenue (Q1, 2026)
      $293.0K
      Net income (Q1, 2026)
      ($46.3M)
      Cash (Q1, 2026)
      $71.5M
      EBIT (Q1, 2026)
      ($40.8M)
      Enterprise value
      $469.8M

      Footer menu